Alert: DEA Moves to Schedule 2C-T-7
Addendum Sept. 2002: 2C-T-7 Scheduled.
(In another notice also published today, the DEA
declared its intention to place the drugs BZP and TFMPP into Schedule I.
To read that notice, see 67 Federal
Register 47341-47343, July 18, 2002).)
The US Drug Enforcement Administration
today published notice that it intends to place the drug 2C-T-7 into
Schedule I of the Controlled Substances Act.
2C-T-7 is being scheduled pursuant to the
DEA’s emergency scheduling powers, meaning that the scheduling could
take effect in as early as 30 days (August 17, 2002).
The DEA’s notice states the factual basis
behind its decision to schedule 2C-T-7.
To the extent that any of the information
relied upon by the DEA may be inaccurate, the Center for Cognitive Liberty
& Ethics (CCLE) and the Multidisciplinary Association for Psychedelic
Studies (MAPS) are seeking your help in correcting the record.
If you spot errors in the following notice,
please immediately send corrections (supported by citations to
published scientific papers) to the CCLE at:
Center for Cognitive
Liberty & Ethics
Below is the DEA’s factual basis for
placing 2C-T-7 in Schedule I. The DEA's complete notice is
available at (67
Federal Register 47343-47345).
** begin DEA quote **
What Is 2,5-Dimethoxy-4-(n)-propylthiophenethylamine?
2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), a
phenethylamine, is structurally related to the Schedule I
phenethylamine 4-bromo-2,5-dimethoxyphenethylamine (2C-B), and other
hallucinogens (e.g., 2,5-dimethoxy-4-methylamphetamine (DOM), and 1-(4-
bromo-2,5-dimethoxyphenyl-2-aminopropane (DOB)) in Schedule I of the
CSA. 2C-T-7 has those structural features of phenethylamines which are
necessary for stimulant and/or hallucinogenic activity; 2C-T-7 is a
sulfur analogue of 2CB. Based on these structural features. 2C-T-7 is
likely to have a pharmacological profile similar to 2CB and other
Schedule I hallucinogens. The similarity in the effects of 2C-T-7 and
2CB has been supported by Shulgin and Shulgin (Pikal: A Chemical Love
Story; pp. 569-570, 1991) and by ``self-reports'' on the Internet.
Shulgin and Shulgin (1991) reported that at an oral dose of 20 mg or 30
mg, 2C-T-7 produced visual hallucinations. They concluded that in terms
of being an acceptable hallucinogen, 2C-T-7 was comparable to 2CB and
mescaline. Self-reports on the Internet have described the
hallucinations resulting from the self-administration of 2C-T-7 as
being very 2CB-like; consisting of persistent multiple images, overlaid
patterns, and trails. The subjective effects of 2C-T-7 have also been
described as being similar to those of 2CB; mood lifting, sense of well
being, emotionally, volatility, increased appreciation of music, and
DEA is not aware of any approved therapeutic use of 2C-T-7 in the
United States. The safety of this substance for use in humans has never
What Information Was Considered in Respect to Making the Finding of
Imminent Hazard to the Public Health?
DEA, as required by 21 U.S.C. 811(h)(3), considered the following
three factors set forth in paragraphs (4), (5) and (6) of 21 U.S.C.
811(c) in its decision to temporarily schedule 2C-T-7. The information
relevant to the three factors is summarized below.
21 U.S.C. 811(c)(4) Its History and Current Pattern of Abuse
The abuse of stimulant/hallucinogenic substances in popular all
night dance parties (raves) and in other venues has been a major
problem in Europe since the 1990s. In the past several years, this
activity has spread to the United States. The Schedule I controlled
substance MDMA and its analogues, collectively known as Ecstasy, are
the most popular drugs abused at these raves. Their abuse has been
associated with both acute and long-term public health and safety
problems. These raves have also become venues for the trafficking and
abuse of ``new non-controlled'' substances in place of or in addition
to ``Ecstasy.'' 2C-T-7 is one such substance.
Illicit use of 2C-T-7 was first reported in Germany in 1997. 2C-T-7
was placed under the control of German law on January 20, 1998. In
October of 1999, 2C-T-7 tablets were being sold in the Netherlands
under the trade name ``Blue Mystic''. Illicit use of 2C-T-7 was
reported in Sweden in January of 2000. Currently 2C-T-7 is controlled
under the Swedish law pertaining to goods which are dangerous to the
public. French Customs authorities reported seizing tablets in 2001
that contained 10 mg of 2C-T-7.
Abuse of 2C-T-7 in the United States was first reported in 1997; an
individual posted his experience associated with the oral ingestion of
20 mg of 2C-T-7 on the Lycaeum website on the Internet. In the year
2000, the abuse of 2C-T-7 by young adults began to spread in the United
States as evidenced by widespread discussion on drug website forums and
the sale of the substance from an Internet company. The information
being discussed on these websites includes the route of administration,
recommended doses, and narratives from individuals describing their
experiences and effects after self-administering 2C-T-7.
Self-reported experiences and other information posted on these
websites indicate that 2C-T-7 is being abused orally (10-50 mg) or
oral route is the most common route of abuse. The powder is being mixed
in liquids or placed in gelatin capsules. Information posted on these
websites indicates that 2C-T-7 is being taken alone or with other
drugs; such as MDMA, ketamine, cannabis, N,N-disopropyl-5-
methoxytryptamine (``Foxy Methoxy'') and N,N-dipropyltryptamine (DPT).
Information gathered by DEA indicates that 2C-T-7 has been
purchased in powder form over the Internet and distributed as such. In
the United States, capsules containing 2C-T-7 powder also have been
encountered; whereas in the Netherlands (``Blue Mystics''), and in
Canada (``Red Raspberry'') the bulk powder is being processed into
21 U.S.C. 811(c)(5) the Scope, Duration and Significance of Abuse
State and local law enforcement agencies reported 2C-T-7 exhibits
seized in the states of Texas and Wisconsin. In Wisconsin, two
unrelated exhibits were submitted to the Wisconsin State Crime
Laboratory for analysis; the first exhibit consisted of two clear
capsules containing 16 to 18 milligrams of white powder and two paper
packets. One packet contained 450 milligrams of tan powder and the
other paper packet contained 869 milligrams. The powder in these
exhibits was identified as 2C-T-7. These two capsules were sold to an
informant as ``Tweety-Bird Mescaline.'' The second exhibit analyzed by
the Wisconsin State Crime Laboratory was shown to be a mixture of 2C-T-
7 and N,N-dipropyltryptamine (DPT). 2C-T-7 has also appeared in illicit
traffic in Tennessee, Washington, and Oklahoma, as evidenced by the 2C-
T-7 related deaths in these states. It is being sold under the ``street
names'' Blue Mystic, T7, Beautiful, Tweety-Bird Mescaline or Tripstay.
To date, DEA has not identified a clandestine laboratory synthesizing
21 U.S.C. 811(c)(6) What, If Any, Risk There Is to Public Health
2C-T-7 shares those structural similarities with 2CB and other
phenethylamines (i.e., DOB, and DOM), which makes it likely to produce
similar public health risks. Sensory distortion and impaired judgment
can lead to serious consequences for both the user and the general
public. 2C-T-7 can have lethal effects when abused alone or in
combination with other illicit drugs. To date, three deaths have been
associated with the abuse of 2C-T-7. The first death occurred in
Oklahoma during April of 2000; a young healthy male overdosed on 2C-T-7
following intranasal administration. The co-abuse of 2C-T-7 with MDMA
will pose a significant health risk if 2C-T-7 popularity increases in
the same venues as with MDMA. The co-abuse of 2C-T-7 with MDMA has
resulted in lethal effects. The other two 2C-T-7 related deaths
resulted from the co-abuse of 2C-T-7 with MDMA. They both occurred in
April of 2001. One young man died in Tennessee while another man died
in the state of Washington.
What Other Factors Were Taken Into Consideration?
Additionally, DEA has considered the three criteria for placing a
substance into Schedule I of the CSA (21 U.S.C. 812). The data
available and reviewed for 2C-T-7 indicate that it has a high potential
for abuse, no currently accepted medical use in treatment in the United
States and is not safe for use under medical supervision.
** end DEA quote **
and Drug Policy Project
Receive Top News
Alerts in your E-mail box! >> Learn